

Reference Data

Fiscal Year 2009

(April 1, 2009 to March 31, 2010)

Consolidated Earnings

- Consolidated Financial Data P 1
- Consolidated Balance Sheets P 2
- Consolidated P/L Statement P 3
- Consolidated Sales Breakdown by Category P 4
- Consolidated Operating Income by Category P 4
- Consolidated Sales -
 - Leading Brands of Self-Medication Operations P 5
- Consolidated Sales -
 - Leading Products of Prescription Pharmaceutical Operations P 6
- Major Subsidiaries : Trend of Sales and Earnings P 6
- Capital Expenditure P 7
- Depreciation Costs P 7
- R&D Expenses P 7
- Subsidiaries and Affiliates P 8

Non-consolidated Earnings

- Non-consolidated Financial Data P 9
- Non-consolidated Sales Breakdown by Category P 10
- Non-consolidated Sales Breakdown by Therapeutic Category P 10
- Shareholders Information P 11

New Drug Development / New Products

- Prescription Pharmaceutical operations:
 - New Drug Development P12
- Launch of New Products P14

Consolidated Financial Data

(Yen Million)

	March 07 (FY06)	March 08 (FY07)	March 09 (FY08)	March 10 (FY09)	(Est.)	
					March 11 (FY10)	
					2Q(4-9)	Full Year
Net Sales	242,071	249,655	256,213	258,441	129,500	262,000
(YOY%)	(-10.8%)	(+3.1%)	(+2.6%)	(+0.9%)	(-0.2%)	(+1.4%)
Self-Medication operations	149,486	152,678	161,141	158,851	84,400	167,200
Prescription Pharmaceutical operations	92,585	96,977	95,072	99,590	45,100	94,800
Gross profit	159,850	164,488	169,462	166,703	83,500	168,300
Selling, general and administrative expenses	137,493	127,535	131,526	132,017	67,000	132,300
Research and development expenses	28,519	24,745	27,523	28,118	11,400	22,100
(% Sales)	(11.8%)	(9.9%)	(10.7%)	(10.9%)	(8.8%)	(8.4%)
Advertising expenses	14,594	14,303	16,531	16,454	8,700	17,300
Sales promotion expenses	27,707	24,793	23,372	24,113	12,600	25,100
Personnel expenses	32,610	32,603	32,947	33,453	17,000	34,100
Operating income	22,357	36,952	37,935	34,686	16,500	36,000
(YOY%)	(-51.8%)	(+65.3%)	(+2.7%)	(-8.6%)	(-9.3%)	(+3.8%)
Ordinary income	24,926	41,896	39,902	36,671	18,000	40,500
(YOY%)	(-49.9%)	(+68.1%)	(-4.8%)	(-8.1%)	(-4.5%)	(+10.4%)
Net income	15,420	25,004	8,815	19,485	10,500	24,500
(YOY%)	(-57.0%)	(+62.1%)	(-64.7%)	(+121.0%)	(+1.3%)	(+25.7%)
EPS (yen)	50.54	84.01	30.01	67.98	37.38	87.23
BPS (yen)	1,832.24	1,816.25	1,745.96	1,816.68	1,827.62	1,865.80
Dividend per share(yen)	27.00	27.00	27.00	27.00	12.00	27.00
Payout Ratio	53.4%	32.1%	90.0%	39.7%	32.1%	31.0%
Capital expenditure	8,066	5,765	5,814	21,132	1,500	5,000
Depreciation and amortization	12,134	11,733	11,014	11,533	5,800	11,700
Total assets	631,929	627,224	591,568	606,443	606,000	616,000
Shareholders' equity	547,486	548,650	514,511	527,760	524,000	535,000
Return on equity(%) *	2.8%	4.6%	1.7%	3.8%	-	4.7%
Return on assets(%) *	2.4%	4.0%	1.4%	3.3%	-	4.0%
Equity ratio(%)	86.3%	86.1%	85.4%	85.3%	84.7%	85.1%
Overseas sales	7,329	11,297	8,184	7,692	-	-
(% Sales)	3.0%	4.5%	3.2%	3.0%	-	-
Number of employees	5,191	5,327	5,409	5,569	-	-

* Average of the beginning and year-end balance of shareholders' equity / total assets

Consolidated Balance Sheets

(Millions of yen)

	End of FY2008		End of FY2009		change	
	March 31, 09)	% total	March 31, 10)	% total		
(Assets)						
I Current assets:	215,872	36.5%	215,686	35.6%	-186	
Cash and deposits	112,989		105,625		-7,364	Acquisition of shares of subsidiary, etc.
Notes and accounts receivable-trade	61,968		60,379		-1,588	
Marketable securities	2,918		7,598		+4,679	Transferred from investment securities:+7,500 Bond redemption:-2,910
Inventories	22,146		23,661		+1,514	Merchandise and finished goods:+1,909, work in progress:-108, raw materials and supplies:-285
Deferred tax assets	7,450		7,711		+261	
Others	8,398		10,709		+2,310	Money trust for repurchase of treasury shares: +2,172
II Fixed assets:	375,696	63.5%	390,756	64.4%	+15,060	
(1) Tangible fixed assets:	92,961	(15.7%)	90,746	(14.9%)	-2,215	
Buildings and structures	48,681		47,136		-1,545	Buildings: -1,560, structures: +15
Machinery and equipment	9,211		8,508		-703	Machinery: -704
Land	29,652		30,828		+1,176	Acquisition of land for new Osaka Branch: +1,169
Others	5,415		4,272		-1,142	Construction in progress: -926
(2) Intangible fixed assets:	10,108	(1.7%)	34,296	(5.7%)	+24,187	
Goodwill	2,484		14,238		+11,753	Goodwill for PT. Taisho Indonesia: +11,884
Sales rights	-		11,252		+11,252	Acquisition of Bristol-Myers Squibb Company sales rights
Trademarks	2,443		4,202		+1,758	Acquisition of Bristol-Myers Squibb Company trademark rights: +2,510 VICKS trademark amortization: -750
Software	4,978		4,210		-767	
Others	202		393		+191	
(3) Investments and other assets:	272,626	(46.1%)	265,714	(43.8%)	-6,911	
Investments in securities	205,410		202,814		-2,595	Bond acquisition: +44,079, Bond redemption: -52,000, Increase in evaluation gain: +13,077, Transferred to marketable securities -7,500
Affiliates' stock	46,706		47,057		+351	
Deferred tax assets	14,121		10,130		-3,990	Decrease due to increase in evaluation gain of investments in securities
Others	6,388		5,711		-677	
Total assets	591,568	100.0%	606,443	100.0%	+14,874	
(Liabilities)						
I Current liabilities:	54,130	9.1%	55,680	9.2%	+1,550	
Notes and accounts payable-trade	20,149		22,689		+2,539	
Accounts payable	11,265		10,228		-1,037	
Accrued corporate tax	9,193		7,972		-1,221	
Allowance for bonuses	4,326		4,433		+106	
Others	9,194		10,357		+1,162	
II Long-term liabilities:	22,927	3.9%	23,002	3.8%	+74	
Reserves for retirement benefits	15,937		16,911		+974	
Deferred taxes liabilities	424		529		+104	
Others	6,565		5,561		-1,004	
Total liabilities	77,057	13.0%	78,682	13.0%	+1,624	
(Net assets)						
I Shareholders' equity	516,948	87.4%	520,697	85.9%	+3,748	
Common Stock	29,804	5.0%	29,804	4.9%	-	
Additional paid-in capital	14,935	2.5%	14,935	2.5%	-	
Retained earnings	535,393	90.5%	506,725	83.6%	-28,667	Net income: +19,485, Payment of dividend: -7,787 Cancellation of treasury stock -40,365
Treasury stock	-63,183	-10.6%	-30,767	-5.1%	+32,416	Acquisition of treasury stock -7,927, Cancellation
II Valuation, translation, adjustments and others	-11,782	-2.0%	-3,147	-0.5%	+8,635	
Unrealized gain on securities	-3,752	-0.6%	4,176	0.7%	+7,928	Increase in evaluation gain of investments in securities
Others	-8,030	-1.4%	-7,323	-1.2%	+706	
III Minority interest	9,344	1.6%	10,210	1.6%	+865	
Total net assets	514,511	87.0%	527,760	87.0%	+13,249	
Total liabilities and net assets	591,568	100.0%	606,443	100.0%	+14,874	

Consolidated P/L Statement

(Millions of yen)

	March 2009 (FY2008)		March 2010 (FY2009)		YOY Change	Explanatory comments
		% Sales		% Sales		
Net sales	256,213	100.0%	258,441	100.0%	+2,228	
Cost of sales	86,889	33.9%	91,815	35.5%	+4,925	Increase mainly due to changes in sales mix
Gross profit on sales	169,324	66.1%	166,626	64.5%	-2,697	
Provision for sales returns	-138		-77		+61	
Gross profit	169,462	66.1%	166,703	64.5%	-2,758	
Selling, general and administrative expenses	131,526	51.3%	132,017	51.1%	+490	
Research and development expenses	27,523		28,118		+594	Increase due to in-licensing-related payments
Advertising expenses	16,531		16,454		-77	
Sales promotion expenses	23,372		24,113		+740	Increase due to increased sales in Prescription Pharmaceutical business
Personnel expenses	32,947		33,453		+505	Increase for retirement benefit expenses
Others	31,150		29,878		-1,272	Decrease for amortization of goodwill
Operating income	37,935	14.8%	34,686	13.4%	-3,249	
Non-operating income	6,968	2.7%	6,795	2.6%	-173	
Non-operating expenses	5,001	1.9%	4,809	1.8%	-191	
Ordinary income	39,902	15.6%	36,671	14.2%	-3,230	
Extraordinary gains	5,417	2.0%	15	0.0%	-5,402	(For same period of previous year) Gain of 4,382 on sale of affiliates' stock Gain of 891 on prior-period adjustment
Extraordinary losses	18,560	7.2%	896	0.4%	-17,664	(For period under review) Loss of 523 due to impairment of idle equipment and facility (For same period of previous year) Losses of 12,852 on lump sum amortization of goodwill, of 2,275 on changes in equity, and of 3,332 on loss on devaluation of investment securities
Income before income taxes and minority interests	26,759	10.4%	35,790	13.8%	+9,030	
Income taxes	16,818	6.6%	15,180	5.9%	-1,638	
Minority interest gain (loss) of consolidated subsidiaries	1,126	0.4%	1,125	0.4%	-1	
Net income	8,815	3.4%	19,485	7.5%	+10,669	

Figures for each quarter are accumulated totals from the beginning of the fiscal year.

Consolidated Sales Breakdown by Category

(Yen Million)

	March 07 (FY06)	March 08 (FY07)	March 09 (FY08)	March 10 (FY09)	(Est.) March 11 (FY10)	
					2Q(4-9)	Full Year
					Self-Medication operations (YOY%)	149,486 (-14.5%)
OTC products, etc.	137,728	140,072	148,229	144,320	76,900	151,300
Foods for Specified Health Use, etc.	8,658	9,826	9,921	10,441	5,500	11,300
Others	3,100	2,780	2,991	4,090	2,000	4,600
Prescription Pharmaceutical operations (YOY%)	92,585 (-4.1%)	96,977 (+4.7%)	95,072 (-2.0%)	99,590 (+4.8%)	45,100 (-6.3%)	94,800 (-4.8%)
Ethical drugs	79,700	81,969	84,712	89,612	41,900	86,600
Others	11,473	10,739	8,748	9,458	3,100	7,800
Royalty income	1,412	4,269	1,612	520	100	400
Total	242,071	249,655	256,213	258,441	129,500	262,000

Consolidated Operating Income by Category

(Yen Million)

	March 07 (FY06)	March 08 (FY07)	March 09 (FY08)	March 10 (FY09)	(Est.) March 11 (FY10)	
					2Q(4-9)	Full Year
					Self-Medication operations (YOY%)	17,384 (-48.3%)
Prescription Pharmaceutical operations (YOY%)	4,973 (-61.1%)	10,781 (+116.8%)	8,707 (-19.2%)	4,227 (-51.5%)	1,800 (-14.3%)	5,700 (+34.8%)
Total	22,357	36,952	37,935	34,686	16,500	36,000

Consolidated Sales - Leading Brands of Self-Medication Operations

(Billions of yen)

	March 07 (FY06)	March 08 (FY07)	March 09 (FY08)	March 10 (FY09)	YOY Change	(Est.) March 11 (FY10)	
						2Q(4-9)	Full Year
						Lipovitan series	73.3
Lipovitan D	52.8	55.2	52.8	49.4	-6.3%	28.3	50.0
Others	20.6	21.4	22.0	21.4	-2.9%	12.2	21.8
(100mL other Lipovitans)	11.3	13.0	13.3	13.1	-1.7%	7.9	13.8
(50mL other Lipovitans)	9.2	8.5	8.7	8.3	-4.7%	4.3	8.0
Pabron series	23.1	23.2	25.4	24.9	-1.7%	9.8	25.0
RiUP series	8.8	10.0	11.4	12.7	+11.9%	6.9	13.5
Naron Series	4.5	4.3	4.4	4.4	+0.1%	2.4	4.7
Gastrointestinal treatment series	4.6	4.2	4.4	4.3	-2.0%	2.0	4.3
Colac Series	3.8	3.6	3.9	3.9	+0.1%	1.9	4.0
ZENA series	4.0	4.1	3.9	3.5	-10.5%	1.7	3.6
Livita series	2.3	2.3	2.6	3.1	+19.6%	1.7	3.5
VICKS series	3.0	3.0	2.9	2.9	+2.2%	0.9	2.9
Overseas drinks	5.0	6.1	6.0	5.7	-3.8%	3.1	6.2

(Rounded to the nearest hundred-million)

Energy Drinks: Domestic Sales Breakdown by Channel (parent basis)

(Billions of yen)

	March 07 (FY06)	March 08 (FY07)	March 09 (FY08)	March 10 (FY09)	YOY Change
Drug-oriented channels	41.4	41.1	39.9	37.1	-7.0%
Food-oriented channels	37.2	40.7	40.0	38.5	-3.6%
Total	78.6	81.7	79.9	75.7	-5.3%

(Rounded to the nearest hundred-million)

Lipovitan D: Domestic Sales Breakdown by Channel (parent basis)

(Billions of yen)

	March 07 (FY06)	March 08 (FY07)	March 09 (FY08)	March 10 (FY09)	YOY Change
Drug-oriented channels	25.1	25.3	23.7	21.4	-9.9%
Food-oriented channels	27.7	29.9	29.1	28.1	-3.4%
Total	52.8	55.2	52.8	49.4	-6.3%

(Rounded to the nearest hundred-million)

Consolidated Sales - Leading Products of Prescription Pharmaceutical Operations

(Billions of yen)

	March 07 (FY06)	March 08 (FY07)	March 09 (FY08)	March 10 (FY09)	YOY Change	(Est.) March 11 (FY10)	
						2Q(4-9)	Full Year
						Clarith	27.3
Palux	11.2	11.4	11.2	10.8	-3.1%	5.1	10.0
Zosyn*	1.0	1.3	4.0	10.7	+168.8%	5.9	12.0
Geninax	-	3.3	3.7	4.8	+29.4%	2.0	5.0
PENTCILLIN	6.1	6.2	5.5	4.3	-21.4%	1.9	3.4
Lorcam	4.3	4.3	4.0	3.7	-6.0%	1.9	3.7
OZEX	3.2	3.4	3.0	2.8	-6.2%	1.3	3.0
TOMIRON	3.5	3.0	3.0	2.5	-15.2%	1.1	2.2
LUPRAC	2.0	2.0	2.1	2.1	+0.5%	1.1	2.1
Metlignine	2.0	2.0	1.9	1.8	-3.7%	0.9	1.7

(Rounded to the nearest hundred-million)

* Figures for March 09 were including sales of Tazocin, and for March 07 and March 08 were sales of Tazocin only

Major Subsidiaries: Trend of Sales and Earnings

Sales and Earnings of Taisho Toyama Pharmaceutical

(Billions of yen)

	March 07 (FY06)	March 08 (FY07)	March 09 (FY08)	March 10 (FY09)	YOY Change	(Est.) March 11 (FY10)	
						2Q(4-9)	Full Year
						Net Sales	80.1
Taisho products	60.5	62.9	61.3	61.3	+0.1%	27.7	58.2
Toyama Chemical products	19.6	19.2	20.5	25.1	+22.7%	12.6	25.3
Operating income	0.1	1.8	3.7	4.0	+8.4%	1.0	2.1
Ordinary income	0.1	1.8	3.7	4.1	+10.9%	1.0	2.1
Net income	-0.7	0.5	1.7	1.9	+13.5%	0.4	0.8

(Rounded to the nearest hundred-million)

Sales and Earnings of Biofermin Pharmaceutical

(Billions of yen)

	March 07 (FY06)	March 08 (FY07)	March 09 (FY08)	March 10 (FY09)	YOY Change	(Est.) March 11 (FY10)	
						2Q(4-9)	Full Year
						Net Sales	7.8
Self medication	-	-	5.5	5.3	-4.0%	2.8	5.2
RX Pharmaceutical	-	-	3.1	3.2	+4.4%	1.6	3.2
Operating income	1.6	2.2	2.1	2.1	+0.7%	1.3	1.9
Ordinary income	1.7	1.9	2.2	2.2	+0.0%	1.3	2.0
Net income	1.0	1.1	1.4	1.2	-10.5%	0.8	1.2

(Rounded to the nearest hundred-million)

The income statement of Biofermin Pharmaceutical Co., Ltd. is consolidated from the first quarter of fiscal 2008, the year ending March 31, 2009.

Consolidated: Capital Expenditure

(Millions of yen)

	March 07 (FY06)	March 08 (FY07)	March 09 (FY08)	March 10 (FY09)	(Est.)	
					March 11 (FY10)	
					2Q(4-9)	Full Year
Total capital expenditure	8,066	5,765	5,814	21,132	1,500	5,000
Taisho Pharmaceutical	7,764	5,553	4,687	19,508	1,200	4,200
Omiya Factory	5,060	1,185	1,404	1,299	400	1,300
Hanyu Factory	114	70	131	39	10	70
Okayama Factory	93	85	58	201	0	80
Research Center	793	899	801	891	300	500
Others	1,704	3,312	2,293	17,076	490	2,250
Subsidiaries	302	211	1,126	1,623	300	800

<Main capital expenditure (fiscal 2009) >

- Non-consolidated: Others

Acquisition of intangible fixed assets (sales rights, trademark rights)

accompanying purchase of Bristol-Myers Squibb Company's OTC business in Asia: ¥14,487 million

Acquisition of land for new Osaka Branch site: ¥1,169 million

Consolidated: Depreciation and amortization

(Millions of yen)

	March 07 (FY06)	March 08 (FY07)	March 09 (FY08)	March 10 (FY09)	(Est.)	
					March 11 (FY10)	
					2Q(4-9)	Full Year
Depreciation and amortization	12,134	11,733	11,014	11,533	5,800	11,700
Cost of sales	4,275	5,410	4,742	4,498	1,900	4,000
SGA expenses	7,859	6,323	6,272	7,035	3,900	7,700

Consolidated: R&D Expenses

(Millions of yen)

	March 07 (FY06)	March 08 (FY07)	March 09 (FY08)	March 10 (FY09)	(Est.)	
					March 11 (FY10)	
					2Q(4-9)	Full Year
Total R&D expenses	28,519	24,745	27,523	28,118	11,400	22,100
Self-Medication operations	7,777	6,051	7,222	5,534	3,200	6,000
Prescription Pharmaceutical operations	20,741	18,693	20,300	22,583	8,200	16,100

Subsidiaries and Affiliates

(As of March 31, 2010)

Company	Address	Capital	Business	Ownership ^{*1}
(1) Consolidated subsidiaries				%
Taisho Kosei Service Co.,Ltd.	Tokyo, Japan	,000 Yen 10,000	SMG	100
Taisho Okinawa Co.,Ltd.	Okinawa, Japan	,000 Yen 50,000	SMG	100
Taisho M.T.C. Co.,Ltd.	Tokyo, Japan	,000 Yen 400,000	SMG	60
Taisho Pharmaceutical Logistics Co.,Ltd.	Saitama, Japan	,000 Yen 30,000	SMG	100
Biofermin Pharmaceutical Co., Ltd.	Hyogo, Japan	,000 Yen 1,227,000	SMG PD	56
Taisho Toyama Pharmaceutical Co.,Ltd.	Tokyo, Japan	,000 Yen 2,000,000	PD	70
Medwell Taisho Co.,Ltd.	Saitama, Japan	,000 Yen 200,000	PD	100
Mejiro Real Estate Co.,Ltd.	Tokyo, Japan	,000 Yen 600,000	SMG	100
Shimoda Central Co.,Ltd.	Tokyo, Japan	,000 Yen 300,000	SMG	100
TAISHO ACTIVE HEALTH Co., Ltd.	Tokyo, Japan	,000 Yen 100,000	SMG	55
Taisho Pharmaceutical (Taiwan) Co.,Ltd.	Taiwan	,000 NT\$ 200,000	SMG	100
Taisho Pharmaceutical California Inc.	U.S.A.	,000 US\$ 41,050	SMG	100
Taisho Pharmaceutical (M) SDN. BHD.	Malaysia	,000 M\$ 24,380	SMG	100
Taisho Pharmaceuticals (Philippines), Inc.	Philippines	,000 Peso 18,900	SMG	100
PT. Taisho Indonesia	Indonesia	,000 rupiah 42,920,000	SMG	100
Taisho Foods Deutschland GmbH	Germany	,000 Euro 306	SMG	100
Taisho Co.,Ltd. Shanghai	China	,000 CNY 132,621	SMG	100
Taisho Pharmaceutical Asia (M) SDN. BHD.	Malaysia	,000 M\$ 26,500	SMG	100
Taisho Pharmaceutical (Europe) Ltd.	United Kingdom	,000 £ 20,000	SMG	100
Taisho Vietnam Co.,Ltd.	Vietnam	,000 VND 170,754,300	SMG	100
Taisho Pharmaceutical (H.K.) Ltd.	China	,000 HK\$ 163,000	SMG	100
Osotspa Taisho Co.,Ltd.	Thailand	,000 THB 15,000	SMG	49
Taisho Pharmaceutical R&D Inc.	U.S.A.	,000 US\$ 4,000	PD	100
PT. Taisho Pharmaceutical Indonesia Tbk	Indonesia	,000 rupiah 10,240,000	SMG	99
Taisho Pharmaceutical Singapore Private Limited	Singapore	,000 US\$ 1,000	SMG	100
(2) Equity Accounting Method				
Toyama Chemical Co.,Ltd.	Tokyo, Japan	,000 Yen 43,550,593	PD	34
Yomeishu Seizo Co., Ltd.	Tokyo, Japan	,000 Yen 1,650,000	SMG	22
Taisho Hizon Manufacturing Inc.	Philippines	,000 Peso 17,000	SMG	50

SMG=Self-Medication operations PD=Prescription Pharmaceutical operations

*1 including indirect ownership

Non-consolidated Financial Data

(Millions of yen)

	March 07 (FY06)	March 08 (FY07)	March 09 (FY08)	March 10 (FY09)	(Est.)	
					March 11 (FY10)	
					2Q(4-9)	Full Year
Net Sales	194,356	201,665	198,856	195,288	96,500	196,000
(YOY%)	(-12.9%)	(+3.8%)	(-1.4%)	(-1.8%)	(-2.5%)	(+0.4%)
Self-Medication operations	142,083	144,801	147,872	145,139	75,400	149,700
Prescription Pharmaceutical operations	52,273	56,864	50,984	50,149	21,100	46,300
Gross profit	128,696	132,993	131,783	128,231	63,800	128,800
Selling, general and administrative expenses	107,188	98,785	99,775	100,523	50,800	98,800
Research and development expenses	28,539	24,765	27,253	27,848	11,200	21,800
(% Sales)	(14.7%)	(12.3%)	(13.7%)	(14.3%)	(11.6%)	(11.1%)
Advertising expenses	14,422	14,008	13,759	13,939	7,400	14,500
Sales promotion expenses	14,287	12,719	12,262	12,408	6,800	13,100
Personnel expenses	17,237	17,402	18,615	18,908	9,700	19,200
Operating income	21,507	34,207	32,007	27,708	13,000	30,000
(YOY%)	(-52.0%)	(+59.1%)	(-6.4%)	(-13.4%)	(-6.4%)	(+8.3%)
Ordinary income	27,527	40,122	38,981	34,226	17,500	38,500
(YOY%)	(-43.8%)	(+45.8%)	(-2.8%)	(-12.2%)	(+3.3%)	(+12.5%)
Net income	16,749	25,910	11,863	21,948	12,000	26,500
(YOY%)	(-53.5%)	(+54.7%)	(-54.2%)	(+85.0%)	(+7.1%)	(+20.7%)
EPS (yen)	54.86	86.99	40.36	76.52	42.69	94.28
Capital expenditure	7,764	5,553	4,687	19,508	1,200	4,200
Depreciation and amortization	11,786	11,399	10,264	10,642	5,300	10,800
Total assets	614,943	604,665	576,022	589,084	589,000	601,000
Shareholders' equity	551,107	547,234	521,995	535,857	536,000	547,000
Return on equity(%) *	3.0%	4.7%	2.2%	4.1%	-	4.9%
Return on assets(%) *	2.6%	4.2%	2.0%	3.8%	-	4.5%
Equity ratio(%)	89.6%	90.5%	90.6%	91.0%	91.0%	91.0%
Number of employees	3,329	3,478	3,516	3,524	-	-

* Average of the beginning and year-end balance of shareholders' equity / total assets

Non-consolidated Sales Breakdown by Category

(Yen million)

	March 07 (FY06)	March 08 (FY07)	March 09 (FY08)	March 10 (FY09)	(Est.)	
					March 11 (FY10)	
					2Q(4-9)	Full Year
Self-Medication operations :	142,083	144,801	147,872	145,139	75,400	149,700
(YOY%)	(-15.8%)	(+1.9%)	(+2.1%)	(-1.8%)	(+0.5%)	(+3.1%)
OTC products, etc.	137,187	139,701	142,288	138,073	71,900	141,600
Foods for Specified Health Use, etc.	3,669	3,708	3,959	4,718	2,400	5,100
Others	1,227	1,392	1,625	2,348	1,100	3,000
Prescription Pharmaceutical operations :	52,273	56,864	50,984	50,149	21,100	46,300
(YOY%)	(-3.7%)	(+8.8%)	(-10.3%)	(-1.6%)	(-11.9%)	(-7.7%)
Ethical drugs	39,673	41,917	40,666	40,169	17,900	38,100
Others	11,188	10,678	8,706	9,460	3,100	7,800
Royalty income	1,412	4,269	1,612	520	100	400
Total	194,356	201,665	198,856	195,288	96,500	196,000

Non-consolidated Sales Breakdown by Therapeutic Category

(Yen million)

	March 07 (FY06)	March 08 (FY07)	March 09 (FY08)	March 09 (FY08)
Nervous system and sensory organ drugs	33,026	33,384	35,716	34,233
Cardiovascular and digestive system drugs	27,485	27,622	28,830	28,393
Nutrient drugs	81,069	83,436	81,511	77,223
Dermatological preparations	17,757	18,294	19,464	21,179
Antibiotics and others	29,876	30,885	27,700	28,952
Foods for Specified Health Use, etc.	3,672	3,710	3,961	4,719
Royalty income	1,472	4,334	1,673	586
Total	194,356	201,665	198,856	195,288

Shareholders Information (as of end of March 2010)

Major Shareholders

(Thousands of Shares)

	Number of shares	% of total
Uehara Memorial Foundation	43,000	15.08%
Shoji Uehara	36,614	12.84%
Taisho Pharmaceutical	15,365	—
Sumitomo Mitsui Banking Corp.	10,000	3.51%
The Bank of Tokyo-Mitsubishi UFJ	10,000	3.51%
Uehara Museum of Modern Art Foundation	10,000	3.51%
Japan Trustee Services Bank, Ltd. (Trust account)	8,411	2.95%
Akira Uehara	7,145	2.51%
Sumitomo Chemical	7,033	2.47%
The Master Trust Bank of Japan, Ltd. (Trust account)	5,602	1.96%

Note(1): Number of shares are rounded down to the nearest 1,000.

% of total calculated excluding treasury stocks (15,365 thousand shares)

Distribution of Shareholders

Financial Institutions	19.85%
Financial Instruments Firm	0.39%
Other companies	35.10%
Foreign Companies	9.78%
Individuals and Others	29.77%
Treasury stocks	5.11%

(Figures are rounded at the second decimal place)

Prescription Pharmaceutical operations: New Drug Development

As of May 14, 2010

(1) Development in Japan

Filed for application

1) Clarith tab. 200

- < Application > Eradication by concomitant therapy (*1) of *H. pylori* in gastric MALT lymphoma, the stomach after endoscopic resection of early stage gastric cancer, and idiopathic thrombocytopenic purpura
- < Description > Macrolide antibiotic
- < Remarks > Additional indication
Joint application with 9 companies (*2)
*1 Consists of a proton pump inhibitor (lansoprazole, omeprazole, and rabeprazole sodium), amoxicillin hydrate, and clarithromycin
*2 Taisho, ABBOTT JAPAN, Astellas, AstraZeneca, Eisai, Kyowa Hakko Kirin, Shionogi, Takeda, Mitsubishi Tanabe

2) CT-081

- < Application > Osteoporosis
- < Development > Co-development with Chugai Pharmaceutical
- < Description > Activated vitamin D₃ derivative
- < Remarks > Applied by Chugai Pharmaceutical
Chugai Pharmaceutical development code: ED-71

Phase 2/3

1) CT-064 (Injection)

- < Application > Osteoporosis
- < Development > Co-development with Chugai Pharmaceutical
- < Description > Antiresorptive bisphosphonate
- < Remarks > Chugai Pharmaceutical development code: R484

Phase 2

1) TT-063

- < Application > Osteoarthritis, scapulohumeral periarthritis, myalgia and other conditions
- < Development > Co-development with Tokuhon
- < Description > Anti-inflammatory analgesic patch formulation containing S-flurbiprofen

2) NT-702

- < Application > Asthma
- < Development > Co-development with Nissan Chemical
- < Description > Expressed bronchodilatation and inhibition of cellular infiltration

3) NT-702

- < Application > Intermittent claudication caused by arteriosclerosis obliterans
- < Development > Co-development with Nissan Chemical
- < Description > Expressed vasodilation as well as platelet aggregate inhibition

Prescription Pharmaceutical operations: New Drug Development

As of May 14, 2010

(1) Development in Japan (continued)

Phase 2

4) CT-064 (Oral)

- < Application > Osteoporosis
- < Development > Co-development with Chugai Pharmaceutical
- < Description > Antiresorptive bisphosphonate
- < Remarks > Chugai Pharmaceutical development code: R484

5) TS-071

- < Application > Type 1 and 2 diabetes
- < Development > In-house
- < Description > Sodium-dependent glucose cotransporter (SGLT) inhibitor

6) TS-022

- < Application > Pruritus caused by atopic dermatitis
- < Development > In-house
- < Description > Prostaglandin derivative
- < Remarks > Overseas: Phase 2

7) Palux

- < Application > Intermittent claudication caused by spinal canal stenosis
- < Development > In-house
- < Description > Prostaglandin E1 preparation
- < Remarks > Additional indication

(2) Development in Overseas Countries

Phase 2

1) TS-022

- < Application > Pruritus caused by atopic dermatitis
- < Development > In-house
- < Description > Prostaglandin derivative
- < Remarks > In Japan: Phase 2

Launch of New Products

As of May 14, 2010

Self-Medication operations

1) Stopan

< Description > A switch-OTC analgesic gastrointestinal treatment formulated with the tiqizium bromide, a prescription-based anticholinergic agent

< Launch > April 2009

2) Diclotect (Tape, Gel and Lotion)

< Description > A switch-OTC topical analgesic and anti-inflammatory drug formulated with the prescription ingredient diclofenac sodium

< Launch > April 2009

3) Lipovitan Half

< Description > A 100 mL energy drink containing half the calories of *Lipovitan D*

< Launch > May 2009

4) RiUP X5

< Description > Pharmaceutical hair regrowth treatment for men formulated with 5% of the active hair regrowth ingredient minoxidil (5 times the amount contained in conventional *RiUP* products)

< Launch > June 2009

5) Flavan-age

< Description > A supplement sold exclusively by mail order that contains a water-soluble and fat-soluble antioxidative constituent

< Launch > June 2009

6) Lipovitan Ace

< Description > An energy drink containing 11 ingredients

< Launch > August 2009

7) Anserine Powdered Green Tea

< Description > A powdered green tea formulated with anserine, a functional food material currently in the limelight

< Launch > September 2009

8) Pabron Mask 365

< Description > A Japanese-made mask manufactured under the same quality controls as hospital-use surgical masks

< Launch > September 2009

Launch of New Products

As of May 14, 2010

Self-Medication operations (continued)
--

9) Lipovitan Gold Ace

<Description> An energy mini-drink containing 4 herbal ingredients
< Launch > October 2009

10) Wakan-no-Katsuryoku

<Description> Health-enhancement supplement sold only through mail order
< Launch > November 2009

11) DENTWELL POs-Ca

<Description> Chewing gum containing POs-Ca, an ingredient developed by Ezaki Glico Co., Ltd.; approved as a Foods for Specified Health Use (FOSHU)
< Launch > November 2009

12) Naturalcare Granules<GABA> (stick-type packaging)

<Description> Powdered green tea containing GABA; approved as a Foods for Specified Health Use (FOSHU)
< Launch > November 2009

13) Benifuuki Powdered Green Tea

<Description> Powdered green tea made from "benifuuki" tea leaves, which contain large amounts of methylated catechins
< Launch > January 2010

14) Dermanin Grande Powder Spray

<Description> Powder spray-type athlete's foot treatment containing terbinafine hydrochloride
< Launch > January 2010

15) Taisho BioDay

<Description> A supplement sold exclusively by mail order that contains bifidobacteria and 3 natural ingredients
Taisho BioDay was jointly developed with Taisho subsidiary Biofermin Pharmaceutical Co., Ltd.
< Launch > March 2010

Launch of New Products

As of May 14, 2010

Self-Medication operations (continued)
--

16) Lipovitan FB

< Description > An energy drink formulated with 300mg of carnitine chloride, which helps in the metabolizing of fat, etc.

< Launch > March 2010

Prescription Pharmaceutical operations
--

1) OZEX fine granules 15% for pediatric

< Description > Japan's first pediatric new quinolone antibacterial agent with indications for pneumonia and otitis media in children

< Launch > January 2010
